Abiogen Pharma is traditionally present in the “Bone Metabolism” market thanks to the marketing of drugs, conceived and developed in its Research Centre and now present throughout the world. This is why Abiogen Pharma is an Italian excellence in the bone pathologies therapy sector and an important reference point on the national scientific scene, thanks to an acknowledged leadership among sector specialists.

Abiogen Pharma commercializes therapies destined both to the treatment of more well-known pathologies such as osteoporosis, bone metastases and osteolysis deriving from multiple myeloma, and to the treatment of rare pathologies such as the Paget syndrome, osteogenesis imperfecta and algodystrophy, also known as Complex Regional Pain Syndrome (CPRS).

Osteoporosis in particular, given its social relevance, is the most widespread pathology among bone diseases, especially owing to fractures due to fragility, which represent the most relevant clinical form. Despite the fact that osteoporotic fractures statistically affect above all post-menopausal women, there is now great awareness of the fact that fractures due to bone fragility are now an important problem also for men.

Algodystrophy is a rare complaint the onset of which manifests itself with pains often located in the limbs and resistant to common painkillers. In some cases, but not always, the onset is due to a traumatic event, but the seriousness of the pain and the trend of the illness are not correlated to the seriousness of the original trauma. The pain is normally associated to edema and a radiological test may highlight a localized osteoporosis that usually regresses with the regression of the illness. The illness is also identified, especially in the English speaking world, as complex regional pain syndrome (CRPS) of type 1 and 2.

Osteogenesis imperfecta encloses a series of hereditary pathologies characterized by defects of one of the two genes, located on chromosomes 7 and 17, responsible for the production of type I collagen. To the characteristic of bone fragility and deformability are associated, in variable measure, other anomalies of the extraskeletal tissues (teeth, skin, ligaments). The presence or lack of these manifestations and their varied seriousness gives rise to a considerable variability of the clinical picture which can include extremely serious forms as well as more moderate or even very slight forms.